BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2026.
World J Clin Oncol. Jan 24, 2026; 17(1): 113304
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.113304
Table 1 Main characteristics of the whole cohort and the groups with survival, n (%)
Characteristics
Overall
Survival
Death
P value
n360151 (41.9)209 (58.1)-
Survive time, median (IQR)22.2 (12, 38.78)38.57 (25.815, 50)15 (8.47, 23.17)< 0.001
Gender0.527
Male287 (79.7)118 (32.8)169 (46.9)
Female73 (20.3)33 (9.2)40 (11.1)
Age, mean ± SD65 (58.75, 70)63.649 ± 7.588864.12 ± 9.4970.602
KPS0.006
706 (1.7)0 (0)6 (1.7)
80144 (40)50 (13.9)94 (26.1)
90208 (57.8)101 (28.1)107 (29.7)
1002 (0.6)0 (0)2 (0.6)
Smoking history0.924
No142 (39.4)60 (16.7)82 (22.8)
Yes218 (60.6)91 (25.3)127 (35.3)
Alcohol history0.409
No153 (42.5)68 (18.9)85 (23.6)
Yes207 (57.5)83 (23.1)124 (34.4)
Tumor location, median (IQR)2 (1, 3)2 (1, 3)2 (2, 3)0.036
Clinical stage< 0.001
I1 (0.3)1 (0.3)0 (0)
II16 (4.4)12 (3.3)4 (1.1)
III206 (57.2)106 (29.4)100 (27.8)
IV137 (38.1)32 (8.9)105 (29.2)
RT dose, median (IQR)65 (60, 66)60 (60, 66)66 (60, 66)0.001
Chemotherapy0.029
No39 (10.8)10 (2.8)29 (8.1)
Yes321 (89.2)141(39.2)180 (50)
BMI, median (IQR)21.6 (19.947, 23.885)22 (20.33, 24.17)21.11 (19.53, 23.44)0.018
Pre-glucose, median (IQR)5.13 (4.71, 5.8225)5.03 (4.605, 5.78)5.24 (4.77, 5.84)0.047
Pre-TC, median (IQR)4.725 (4.0475, 5.3625)4.82 (4.06, 5.425)4.69 (4.01, 5.3)0.410
Pre-TG, median (IQR)1.13 (0.8975, 1.45)1.12 (0.9, 1.45)1.13 (0.89, 1.46)0.880
Post-BMI, mean ± SD20.89 (19.325, 22.58)21.537 ± 2.698320.904 ± 2.66110.072
Post-glucose, median (IQR)5.31 (4.81, 5.94)5.26 (4.825, 5.915)5.33 (4.8, 5.94)0.886
Post-TC, median (IQR)4.48 (3.87, 5.29)4.64 (4.025, 5.525)4.26 (3.73, 5.17)0.002
Post-TG, median (IQR)1.3 (0.9875, 1.67)1.43 (1.1, 1.775)1.23 (0.92, 1.53)< 0.001
PreTyG, median (IQR)8.4781 (8.1915, 8.7593)8.4357 (8.1754, 8.7729)8.5087 (8.207, 8.748)0.393
PostTyG, mean ± SD9.8787 ± 0.318569.9299 ± 0.293199.8418 ± 0.331490.009
PostTyG-BW, median (IQR)82.961 (73.243, 92.833)85.855 (74.724, 96.954)80.109 (72.236, 89.091)0.004
PostTyG-BMI, median (IQR)214.85 (195.92, 234.25)218.76 (202.14, 237.33)211.38 (192.76, 230.09)0.006
Table 2 Pearson correlation coefficients between post-treatment triglyceride-glucose-related indices and clinical characteristics
Group
TyG index
Clinical stage
RT dose
Chemotherapy
BMI
Survival time
Survival status
Total patientsPostTyGR-0.133-0.0240.0790.049-0.1250.119
P value0.0120.6450.1360.3510.0170.023
FDR P value0.0360.5720.2940.3410.3410.045
PostTyG-BWR-0.2180.0520.1330.787-0.1510.2
P value< 0.0010.3290.012< 0.0010.004< 0.001
FDR P value0.7390.5720.7390.1630.5010.402
PostTyG-BMIR-0.2210.0590.1640.971-0.1460.21
P value< 0.0010.2640.002< 0.0010.005< 0.001
FDR P value0.0010.460.033< 0.0010.0140.033
MalePostTyGR-0.19-0.0160.0960.075-0.1150.142
P value0.0010.790.1040.2040.0510.016
FDR P value0.0080.6150.1960.3410.2880.112
PostTyG-BWR-0.2450.0720.1740.821-0.1630.257
P value< 0.0010.2230.003< 0.0010.006< 0.001
FDR P value0.9570.4580.7790.0330.5720.485
PostTyG-BMIR-0.2220.1210.1820.969-0.1520.269
P value< 0.0010.040.002< 0.0010.01< 0.001
FDR P value0.0020.2880.033< 0.0010.0020.042
FemalePostTyGR0.089-0.0740.023-0.047-0.1560.029
P value0.4530.5350.8490.6910.1870.807
FDR P value0.6790.7870.9570.8230.9880.415
PostTyG-BWR-0.158-0.2120.1170.726-0.124-0.018
P value0.1830.0710.323< 0.0010.2960.88
FDR P value0.4530.7790.790.5580.7390.572
PostTyG-BMIR-0.195-0.2580.1170.964-0.106-0.055
P value0.0980.0280.323< 0.0010.3730.641
FDR P value0.4580.4470.558< 0.0010.820.541